Life Sciences Archive » December, 2024

Life Sciences - December, 2024

185 articles

• Ex-Pharma Exec Charged With $38M Insider Trading Scheme
• HHS Can't Enforce Abortion Privacy Rule Against Texas Doctor
• Sens. Aim To Protect Generics With Skinny Labels In New Bill
• South Korean Needle Operation Secures Patent Win At ITC
• Fed. Circ. Says Teva Inhaler Patents Can't Be In Orange Book
• Hagens Berman Settles Suit Over Effexor Deal Atty Fees
• Nippon Owes $115M In Muscular Dystrophy IP Fight, Jury Says
• The Most Significant Trade Secrets Cases Of 2024
• Top Product Liability Cases Of 2024
• Psychedelics Law Reformers Hit Multiple Setbacks In 2024
• Reviewing 2024's Crucial Patent Law Developments
• Fla. Labs Appeal $7.3M Conn. Jury Verdict Favoring Cigna
• Top Privacy & Cybersecurity Developments Of 2024
• 7th Circ. Upholds $900K Punitive Damages Award In TM Case
• Capital Markets Attorneys Ready For Reset After Bumpy 2024
• Fixing Up Cars Makes Me A Better Lawyer
• Ex-Biopharma Exec Settles SEC Insider Trading Claim
• Judge Says Some Paraquat Plaintiffs Being Left In Dark
• PhRMA Wins Bid To Halt W.Va. Drug Discount Expansion Law
• FTC Says PBMs Can't Get Preliminary Block In Insulin Case
• Foley Adds Tech, Life Sciences Partner From IP Boutique
• Judge Wrongly Axed $107M IP Verdict, Pfizer Tells Fed. Circ.
• Biotech Co. Hid Eye Drug's Safety Risks, Investor Says
• Medical Supplies Giant, Drone Operator File Confidential IPOs
• McKesson Urges Justices To Keep Hobbs Act's 'Exclusivity'
• Medical Device Investors Get Final OK On $15M Deal
• Generic-Drug Cos. Get State AGs' Trial Order Flipped
• Labcorp Settles Competition Suit Against Ex-Sales Exec
• FDA Declaration May Restart Compounders' Shortage Suit
• Fresenius Loses Invalidity Argument In Nausea Drug IP Fight
• Making The Pitch To Grow Your Company's Legal Team
• Data Privacy Landscape After Mass. Justices' Wiretap Ruling
• Philips CPAP Suits Against SoClean Tossed From MDLs
• Pharma Trial Consultant To Pay SEC $3M Over Insider Trading
• Vaxart Investors Win Class Cert. Over COVID Shot On 2nd Try
• Patent Limits For Biosimilar Litigation Lands In Spending Bill
• FDA's Gastro Drug Fast-Track Denial Survives DC Circ.
• J&J Unit Beats Schizophrenia Drug IP Challenge On Remand
• State AGs, Generic Cos. Fight Over Price-Fixing Trial Order
• Judge Eyes Limits To Medical Device Co.'s Poaching Verdict
• The Future Of GLP-1 Policy After Drug Shortage Ends
• CVS Fueled Opioid Epidemic In Rush For Profits, Feds Say
• Amgen Hit With $50M Infringement Verdict Over Leukemia Drug
• FTC Wants Express Scripts' Defamation Suit Tossed
• Using Contracts As Evidence Of Trade Secret Protection
• RJ Reynolds Asks Justices To Toss Forum Shopping Argument
• SiteOne Gets $100M To Advance Non-Opioid Pain Treatments
• 11th Circ. Urged To Block Abortion Clinic Buffer Zone Law
• Laser Maker Loses Bid To Trim Patent Suit In Mass.
• Express Scripts, OptumRx Can't Ditch LA County Opioid Suit
• Sandoz Cuts $275M Deal For More Price-Fixing Claims
• Stanford Profs Say Roche's Trade Secret Claims Time-Barred
• House GOP Asks CVS How Its PBM Treats Smaller Pharmacies
• The Biggest Georgia Legal Developments Of 2024
• Feds Intervene In $200M FCA Case Against CVS
• Drug Co. Investor Sues In Del. Over $140M Insider Windfall
• When US Privilege Law Applies To Docs Made Outside The US
• Looking For Patterns In Pharmaceuticals' Use Of AI Patents
• Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement
• Becton Dickinson To Pay SEC $175M Over Pump Claims
• 11th Circ. Appears Wary Of Doc's New Trial Bid In $27.5M Case
• The Biggest Patent Decisions Of 2024
• The State Of USPTO Rulemaking At The End Of Vidal's Term
• Allele, Regeneron Settle COVID Treatment Patent Suit
• Supreme Court Rejects Salix Appeal In IBS Drug Case
• 2024 IPO Market Trends, And What To Expect Next Year
• With Legal Battle Looming, Neb. Legalizes Medical Marijuana
• Medical Device Co. Brass Hid SPAC's True Value, Suit Says
• Pharma Co. Brass Face Investor Suit Over Drug Trial Probe
• J&J Unit Deemed Family Duties A 'Distraction,' Suit Says
• What's Left In $400M Skinny Label Row? A Lot, Court Says
• Pa. Contractor Hit With $4.2M Verdict In Pot Software Row
• Sexual Abuse, Price-Gouging Bills Clear Michigan Senate
• Feds Narrow Drug Case Against Wife Of Convicted Drexel Prof
• Philly Atty Gets Harsher Discipline In NJ For Pill Mill Conviction
• Taxation With Representation: Kirkland, Davis Polk, Wachtell
• What 2024 Trends In Marketing, Comms Hiring Mean For 2025
• McKinsey To Pay $650M For Work With Opioid Maker Purdue
• Moderna Fires Back With Counterclaims In GSK RSV Vax Suit
• Align Tech's $27.5M Antitrust Deal Hits Nerve With Judge
• Pharma Co. Says Federal Court Must Weigh Atty Fee Bid
• Medicare Could Lose Billions From 'Patent Abuse,' Group Says
• Bausch And Lomb Says Potential Sale In The Works
• Wash. Justices OK Tax Break For Pharmacy Benefits Manager
• J&J Shampoo Contamination Suit Sent Down The Drain
• MOVEit Data Breach MDL Survives Dismissal Bid
• How Trump's Tariff Promises May Play Out In 2nd Term
• Cooley Wins Bid To Arbitrate Fla. Malpractice Suit
• Group Running Makes Me A Better Lawyer
• Montana Justices Uphold Temporary Block On Trans Care Ban
• AADI Enlists NY Court To Enforce Cancer Drug Award
• Ga. Judge Refuses To Reconsider Toss Of Patient Data Suit
• High Court Bar's Future: Haynes Boone's Daniel Geyser
• Neb. Medical Pot Legalization Hit With New Legal Challenge
• 6 Changes I Would Make If I Ran A Law School
• Predictions For Trump Antitrust Enforcement Of Life Sciences
• Kirkland-Led Patient Square Pays $4.1B For Animal Health Co.
• Md. Jury Convicts Ex-Biotech Execs On Some Fraud Counts
• Paul Hastings Says Biz Waived Privilege On Malpractice Docs
• Bristol-Myers Said To Renege On $450M Milestone Promise
• Judge Won't Cull EpiPen Antitrust Action Against Mylan
• PTAB Grapples With MRNA History In COVID Vax Dispute
• 9th Circ. Says Idaho Can't 'Veto' Federal Law In Abortion Row
• Ex-CEO Argues Arbitrator's Failure To Disclose Sinks Award
• FTC's Holyoak Says Chair OK With Some Cartels
• Beasley Allen Told To Give Update On J&J Discovery
• Nutraceutical Patent Insights As Market Heats Up
• Eli Lilly Says Tampa Health Biz Can't 'Pass The Buck' In TM Suit
• Labcorp Accuses Ex-Sales Exec Of Stealing Customers
• BioNTech, Pfizer Rival Wants Party Flip In COVID Vax IP Fight
• Ohio Justices Reject Opioid Nuisance Claims In $650M Appeal
• Firms Still Have The Edge In Lateral Hiring, But Buyer Beware
• Akin Gump 'Totally Messed Up' With Texts, Vaxart Judge Says
• Intellia Can't Escape Patent Suit Over $100M Regeneron Deal
• 9th Circ. Tosses Regal Cinemas' COVID Coverage Suit
• Condom Co. Says Rival Owes $744K In 'Naked' IP Dispute
• What 2024 Election Means For Drugs, Medicare And Medicaid
• UCLA Student Sues Doctors Over Transgender Misdiagnosis
• Prevagen Maker Ordered To Cease Memory Claims
• High Court Won't Hear Zimmer Biomet Royalties Fight
• Think Like A Lawyer: 1 Type Of Case Complexity Stands Out
• SEC Says Market Forecaster Ran Biotech Pump-And-Dump
• Philly Jury Clears B. Braun In Cancer Emissions Case
• Judge Denies Publix Bid To Appeal Opioid Coverage Ruling
• Galderma Can't Undo Lupin's Skin Drug Win At Fed. Circ.
• Google Must Face Trimmed BIPA Suit Over IBM Dataset
• 9th Circ. Won't Revisit CR Bard's Patent Misuse Win
• AngioDynamics Port Defect Caused Infection, Ga. Man Says
• What Bisphenol S Prop 65 Listing Will Mean For Industry
• Anthem Wants Testing Lab's $3.8M Suit Axed Or Split Up
• Creditor Says Failed Solar Biotech Bidder Shouldn't Get Fee
• Philips Medical Monitoring Deal, $4.8M Fees Get Final OK
• Fed. Circ. Ruling Shows Importance Of Trial Expert Specificity
• Husband Of Ex-Takeda Exec Convicted For $2M Invoice Fraud
• UK Litigation Roundup: Here's What You Missed In London
• Think Like A Lawyer: Note 3 Simple Types Of Legal Complexity
• Fed. Circ. Grapples With Injunctions On Eylea Biosimilars
• IP Forecast: PTAB To Hear Pfizer Fight Over COVID-19 Patents
• Fla. Labs Say Cigna's Trial 'Confession' Erases $7.3M Verdict
• Gov't Efficiency Push Is A 'New Day,' House Speaker Says
• FINRA Fines Firm $900K Over SPAC Underwriting Fee Issues
• Abbott Accused Of 'Last-Ditch Effort' To Halt Formula Suit
• Quest Ex-Workers Ask 3rd Circ. To Revive 401(k) Suit
• Justices Mull Sex-Based Classification In Trans Law Case
• SpaceX Seeks Astronomical $350B Value, And More Rumors
• FDA Warns 115 Retailers Over Unauthorized E-Cigarettes
• Gardening Makes Me A Better Lawyer
• Insulet Wins $452M In Trade Secret Theft Trial
• Withers IP Partners Hop To Sullivan & Worcester
• Novartis Fails To Stop Generic Drug Release At Fed. Circ.
• Jackson's 'Quite Worried' About Equal Protection Precedent
• JSR Wins As Fed. Circ. Axes Cytiva Antibody Isolation Patents
• Colo. Co.'s Alleged Kickback Scheme Ends In $2M Settlements
• DEA Judge Sets Pot Rescheduling Hearings
• Fed. Circ. Judge Condemns 'Nonsense' Law In Antibody Fight
• Takeda Exec Duped Beau Into $2M Fraud, Jury Told
• Justices Seem To Back Ban On Transgender Youth Care
• Litigation Inspiration: Reframing Document Review
• Mich. AG Deal, NIH 4th Circ. Win And X Corp Bid In HIPAA Row
• Calif. Unveils Reproductive Rights Bills To Prep For Trump
• SEC Says Biopharma's Cooperation Helped It Avoid Penalty
• J&J's Neosporin Forever Discolored Man's Groin, Suit Says
• $1B Sandoz Placeholder Bid Needs More Support, Judge Says
• USPTO Abandons Polarizing Proposal Over Double Patenting
• Vidal Aimed To Put USPTO Rulemaking In The Spotlight
• Key Takeaways From FDA's Latest Social Media Warnings
• FDA Issues Guidance On Potential Infant Formula Shortages
• 4 Mass. State Court Rulings You May Have Missed In Nov.
• VA Announces Study On MDMA-Assisted Therapy For Vets
• Expect More State Scrutiny Of PE In Healthcare M&A
• Declaring Unexpected Results: Pitfalls For Rule 132 At PTAB
• House COVID-19 Probe Points to China 'Lab Leak'
• Judge Isn't Seeing 'Good Faith' Compliance In Probiotic Feud
• Justices Seem Inclined To Back FDA Block Of Flavored Vapes
• Investor Alleges Medical Device Co. Misled On FDA Clearance
• Hagens Berman Sued For Slice Of Atty Fee From Effexor Deal
• Chancery OKs $21M Deal To End Gene Co. Class Suit
• Fla. Tribe Sues Eli Lilly, CVS, Others Over Insulin Price-Fixing
• Heritage's $10M Generic Drugs Deal With AGs Gets 1st OK
• IP Ruling Likely To Limit Arguments Against Qualified Experts
• How Boards And Officers Should Prep For New Trump Admin
• DEA Asserts Its Role As Proponent Of Pot Rescheduling Plan
• Ex-Parexel Worker Says Vax Rule Lacked 'Informed Consent'
• Shipping Industry Braces For Waves Of New Trump Tariffs
• Co-Worker's Affair Isn't Harassment, Research Co. Tells Court